SCHEMBL24303045

SCHEMBL24303045

CC(=O)c1c(OCc2ccccc2)ccc2ncccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
PPIA P62937 2/20 0.46
LTA4H P09960 1/20 0.44
MAPK14 Q16539 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
BRD4 O60885 1/20 0.44
MAOB P27338 2/20 0.43
NSD2 O96028 1/20 0.43
SLC40A1 Q9NP59 1/20 0.43
CASP3 P42574 2/20 0.42
SENP8 Q96LD8 2/20 0.42
SENP7 Q9BQF6 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4531027 0.81 CA9 (0.64) CA9SMN1; SMN2L3MBTL1MAPTCYP2C9
SCHEMBL27032736 0.78 L3MBTL1 (0.48) SMN1; SMN2L3MBTL1MAPTTDP1KDM4E
SCHEMBL4947232 0.77 MAOB (0.61) CA9SMN1; SMN2L3MBTL1MAPTCYP2C9
SCHEMBL3307110 0.76 MAPT (0.56) SMN1; SMN2L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL23640344 0.76 MAPK14 (0.50) SMN1; SMN2L3MBTL1MAPTTDP1PPIA
SCHEMBL27656755 0.75 KDM4E (0.46) SMN1; SMN2L3MBTL1MAPTTDP1LTA4H
SCHEMBL4691988 0.75 LTA4H (0.55) SMN1; SMN2L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL29836285 0.75 LTA4H (0.55) SMN1; SMN2L3MBTL1MAPTCYP2C9CYP2C19
SCHEMBL2799479 0.74 LTA4H (0.58) SMN1; SMN2L3MBTL1MAPTTDP1PPIA
SCHEMBL27592091 0.74 LMNA (0.46) MAPTLTA4HMAPK14MRGPRX4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CRBN, CSNK2A1, CSNK2A2 CA9 3412/4885SMN1; SMN2 2099/4885L3MBTL1 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.